Drug intelligence / Profile preview

Fibore

Development stage: Phase 3
Lead developer: FibroGen
Modality: Small Molecules
Administration: Topical

Overview

**Fibore** is an investigational topical boron-based gel containing 3% sodium pentaborate pentahydrate. It has been studied for prevention of radiation dermatitis in patients receiving radiotherapy for breast cancer. Its proposed activity includes antioxidant and skin-protective effects, potentially involving increased glutathione activity, modulation of inflammatory cytokines and tissue-remodeling enzymes, improved skin hydration, and support of wound healing. A completed randomized, double-blind Phase 3 trial evaluated the gel for prevention of radiotherapy-associated dermatitis. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/boron-based-gel))

Brand names: Fibore
Other names: boron-based gel

Beyond the preview

Go deeper on Fibore.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibore.

Explore the full profile